Pluri (PLUR) Non-Current Debt (2021 - 2025)
Pluri (PLUR) reported Non-Current Debt of $24.9 million for Q1 2025, up 3.67% year-over-year from $24.1 million in Q1 2024, and up 4.83% quarter-over-quarter from $23.8 million in Q4 2024.
Pluri (PLUR) Non-Current Debt (2021 - 2025) Analysis & Trends
Pluri (PLUR) has 5 years of Non-Current Debt data on file, last reported at $24.9 million in Q1 2025.
- Non-Current Debt for Q1 2025 came in at $24.9 million, up 3.67% year-over-year; the trailing twelve-month figure through Mar 2025 was $24.9 million (up 3.67% YoY), and the FY2024 annual result was $24.0 million, up 2.11% from the prior year.
- Non-Current Debt improved to $24.9 million in Q1 2025 per PLUR's latest filing, from $23.8 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $25.4 million in Q3 2024 and troughed at $20.7 million in Q3 2022.
- A 5-year average of $23.4 million and a median of $23.5 million in 2021 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2022 and 2023: Non-Current Debt declined 11.61% in 2022, then climbed 11.82% in 2023.
- A 5-year view of Non-Current Debt shows it stood at $23.2 million in 2021, then slipped by 2.09% to $22.7 million in 2022, then advanced by 7.61% to $24.4 million in 2023, then declined by 2.47% to $23.8 million in 2024, then climbed by 4.83% to $24.9 million in 2025.
- Business Quant data shows PLUR's Non-Current Debt at $24.9 million in Q1 2025, $23.8 million in Q4 2024, and $25.4 million in Q3 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 319.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Pluri | 21.39 Mn | 21.87 Mn | 86,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 24.95 Mn |
| Mar 31, 2025 | 24.95 Mn |
| Dec 31, 2024 | 23.80 Mn |
| Dec 31, 2024 | 23.80 Mn |
| Sep 30, 2024 | 25.37 Mn |
| Sep 30, 2024 | 25.37 Mn |
| Jun 30, 2024 | 24.03 Mn |
| Jun 30, 2024 | 24.03 Mn |
| Mar 31, 2024 | 24.07 Mn |
| Mar 31, 2024 | 24.07 Mn |
| Dec 31, 2023 | 24.40 Mn |
| Dec 31, 2023 | 24.40 Mn |
| Sep 30, 2023 | 23.17 Mn |
| Sep 30, 2023 | 23.17 Mn |
| Jun 30, 2023 | 23.53 Mn |
| Jun 30, 2023 | 23.53 Mn |
| Mar 31, 2023 | 23.35 Mn |
| Mar 31, 2023 | 23.35 Mn |
| Dec 31, 2022 | 22.68 Mn |
| Dec 31, 2022 | 22.68 Mn |